Online Trial Tracker - Larvol Sigma

Neoplasms, Connective and Soft Tissue

Talzenna (talazoparib)

Phase 1

Welcome, Profile Billing Logout

1 Trials

All TrialsPhase 1

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Talzenna (talazoparib) / Pfizer

NCT01286987 / 2010-023062-40: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

	From trial in BRCA mutated breast cancer patients at ASCO 2014
	May 2014 - Jun 2014: From trial in BRCA mutated breast cancer patients at ASCO 2014
	At ASCO 2014
	May 2014 - Jun 2014: At ASCO 2014
	From BRCA mutated ovarian cancer patients at ASCO 2014
	May 2014 - Jun 2014: From BRCA mutated ovarian cancer patients at ASCO 2014
	For breast cancer, ovarian cancer and small cell lung cancer
	May 2014 - May 2014: For breast cancer, ovarian cancer and small cell lung cancer
	Additional data at ECCO/ESMO for breast cancer
	Sep 2013 - Sep 2013: Additional data at ECCO/ESMO for breast cancer
	ECCO-ESMO-ESTRO 2013
	Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
	Data presentation of BRCA ovarian, BRCA breast and solid tumors at ASCO 2013
	Jun 2013 - Jun 2013: Data presentation of BRCA ovarian, BRCA breast and solid tumors at ASCO 2013
More

Completed

113

US, Europe

Talazoparib, BMN 673, MDV3800

Pfizer, Medivation, Inc.

Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer

03/15

01/17

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites